Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial (Q36467826)

14 August 2017

Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial (English)

1 reference

14 August 2017

hepatocellular carcinoma

1 reference

1 reference

Lai CL

1

1 reference

14 August 2017

Wu PC

2

1 reference

14 August 2017

Lok AS

3

1 reference

14 August 2017

Lin HJ

4

1 reference

14 August 2017

Ngan H

5

1 reference

14 August 2017

Lau JY

6

1 reference

14 August 2017

Chung HT

7

1 reference

14 August 2017

Ng MM

8

1 reference

14 August 2017

Yeoh EK

9

1 reference

14 August 2017

Arnold M

10

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 December 1989

1 reference

British Journal of Cancer

14 August 2017

1 reference

14 August 2017

60

1 reference

14 August 2017

6

1 reference

14 August 2017

928-933

1 reference

Clinical features of hepatocellular carcinoma: Review of 211 patients in Hong Kong

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247256

Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247256

NIH conference. Hepatocellular carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247256

Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247256

alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247256

Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247256

Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247256

Primary hepatocellular carcinoma—etiology, pathogenesis, and prevention

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247256

Adriamycin cardiotoxicity

21 September 2018

1 reference

12 December 2020

Clinical, serologic, and immunologic effects of human leukocyte interferon in HBsAg-positive primary hepatocellular carcinoma

1 reference

12 December 2020

Human lymphoblastoid interferon. In vitro and in vivo studies in hepatocellular carcinoma

1 reference

12 December 2020

Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1989.392

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

2557881

1 reference